Answers are grounded in this paper and cite their sources.
Case series reports ocular toxic effects and management outcomes in patients with folate receptor α–positive gynecologic cancers, highlighting treatment safety strategies.
This case series describes the management and outcomes of ocular toxic effects associated with mirvetuximab soravtansine therapy in female patients with folate receptor α–positive gynecologic malignant neoplasms.
No takes yet. Share an insight, caveat, or question.
Haidar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: